Key clinical point: First-line therapy with palbociclib plus an aromatase inhibitor (AI) vs only AI improved survival outcomes in elderly patients (age ≥75 years) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC).
Major finding: Patients receiving palbociclib + AI combination therapy vs only AI had a significantly improved overall survival (hazard ratio 0.66; P = .0007), real-world progression-free survival (hazard ratio 0.72; P = .0021) and prolonged time to receiving chemotherapy (hazard ratio 0.69; P = .0014).
Study details: This sub-analysis of the retrospective observational P-REALITY X cohort study included 961 patients with HR+/HER2− metastatic BC who were age ≥ 75 years and received either palbociclib + AI (32.6%) or only AI (67.4%) as first-line therapy.
Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer. The other authors declared receiving research grants, consulting or advisory fees, honoraria, or sponsorship for research from Pfizer and other sources.
Source: Brufsky A et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751 (Sep 28). doi: 10.3389/fonc.2023.1237751